4 Stocks Driving The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 34 points (-0.2%) at 14,831 as of Friday, April 12, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 825 issues advancing vs. 2,080 declining with 130 unchanged.

The Drugs industry currently sits down 0.60 versus the S&P 500, which is down 0.51. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.58.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. Shire ( SHPG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Shire is up $1.26 (1.39) to $91.93 on average volume Thus far, 246,818 shares of Shire exchanged hands as compared to its average daily volume of 357,000 shares. The stock has ranged in price between $91.60-$92.22 after having opened the day at $91.95 as compared to the previous trading day's close of $90.67.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $16.8 billion and is part of the health care sector. The company has a P/E ratio of 22.9, above the S&P 500 P/E ratio of 17.7. Shares are down 2.6% year to date as of the close of trading on Thursday.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Shire Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead